

# Recommendations: High-risk Spring 2023 COVID-19 Vaccine Booster Dose Program in Ontario

Published: March 21, 2023

## Overview

On January 11, 2023, the Ontario Immunization Advisory Committee (OIAC) met to discuss program planning considerations to help inform future planning of the 2023 COVID-19 vaccine program at the request of the Ontario Ministry of Health (MOH).<sup>1</sup> At that time, the OIAC did not feel that detailed recommendations for all of 2023 could be outlined, and planned to revisit this topic in February 2023.

In anticipation of the February 2023 meeting, the MOH requested OIAC address two specific questions related to a potential spring 2023 high-risk booster campaign:

1. Which high-risk groups should be included in a spring high-risk booster campaign?
2. What is the recommended interval between date of last dose or confirmed COVID-19 infection and date of a spring 2023 booster dose?

The OIAC reconvened on February 8 and 22, 2023 to review considerations and evidence to inform recommendations regarding these questions. This document provides a summary of the considerations and OIAC's recommendations.

---

## Recommendations

1. All individuals eligible for a COVID-19 vaccine primary series who have not yet been vaccinated should be vaccinated
2. All individuals eligible for a fall 2022 booster dose who have not yet been vaccinated with their fall 2022 booster should receive it, if it has been at least six months since infection or last vaccine dose
3. In addition, an Ontario spring high-risk COVID-19 booster campaign should target the following high-risk groups:
  - a. Individuals aged 65 years and older
  - b. Residents of long-term care homes, retirement homes, Elder Care Lodges and individuals aged 18 years and older living in other congregate settings that provide assisted-living and health services
  - c. Pregnant individuals
  - d. Individuals aged 18 years and older who are moderately to severely immunocompromised

4. The Ontario Ministry of Health should consult and work in partnership with marginalized communities and groups in Ontario to improve equitable uptake and access to COVID-19 immunization services
  5. A six-month interval is recommended from previous infection or last vaccine dose for the timing of eligibility for an additional dose as part of a spring high risk program
- 

## Summary of Considerations

The OIAC reviewed the COVID-19 vaccine program goals to minimize serious illness and deaths while minimizing societal disruption as a result of the COVID-19 pandemic outlined by the Council of Chief Medical Officers of Health (CCMOH).<sup>2</sup>

The OIAC also reviewed and discussed current Ontario COVID-19 epidemiology, including:

- variants of concern (VOC)
- risk factors for severe infection, including the importance of age
- bivalent vaccine safety and effectiveness
- hybrid immunity

Additionally, the committee reviewed Ontario COVID-19 vaccine guidance<sup>3</sup> and booster dose uptake in the province, as well as immunization advisory committee statements from other jurisdictions, recommendations for past booster dose programs (including Ontario's spring 2022 program which focused on older adults<sup>4</sup>), and current recommendations across jurisdictions for spring 2023 booster doses.

## Risk factors for severe disease

- Vaccination continues to play a pivotal role in reducing the risk of severe outcomes due to COVID-19.
- Increasing age continues to be the most important risk factor for hospitalization and death due to COVID-19, including among those who have been vaccinated.<sup>5-9</sup> With the highest rates of severe outcomes occurring among older adults<sup>5</sup>, the additional protection provided from a bivalent dose this spring will have the greatest impact in this age group.
- Emerging data demonstrate a difference in vaccine protection against hospitalizations due to COVID-19, including in older adults, by history of past infection.<sup>10,11</sup> Individuals who have been vaccinated and who have evidence of a past infection (i.e., hybrid immunity) have been shown to have better and more sustained protection against hospitalization relative to those who were vaccinated alone (i.e., without a past history of infection).<sup>10,11</sup> Among adults in Canada, the proportion of those who have been previously infected with COVID-19 is lowest for adults over 60 years of age, relative to other age groups.<sup>12</sup> As such, the benefit of an additional dose in the spring of 2023 is likely to be greatest among those who have not been previously infected, in particular older adults who are also less likely to have been previously infected.

- Residents of long-term care homes, retirement homes, Elder Care Lodges and individuals living in other congregate settings that provide assisted-living and health services; adults who are moderately to severely immunocompromised; and pregnant individuals have been identified as groups at high-risk of severe outcomes and previous immunization recommendations have highlighted the importance of booster doses in these groups.<sup>3,6,7,13</sup> Further, the decline in protection offered by the monoclonal antibody product Evusheld (tixagevimab and cilgavimab) in the context of current variants may be an additional consideration for a spring booster dose for immunocompromised populations.<sup>14,15</sup>

## Bivalent vaccine safety and effectiveness

- Bivalent mRNA vaccine products have been shown to have a similar safety profile to original mRNA vaccine formulations with similarly low frequencies of adverse events following immunization. A preliminary signal flagging a possible link between the Pfizer-BioNTech COVID-19 bivalent (BA.4/BA.5) vaccine and ischemic stroke in individuals aged 65 years and older was announced by the United States (US) Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) in January 2023.<sup>16,17</sup> This possible signal was based on analyses from one US data system and has not been identified in multiple other vaccine safety surveillance systems used in the US. Further, no other country, including Canada, has identified any similar increased risk of ischemic stroke following bivalent vaccines.<sup>18</sup> The CDC has recommended no change in vaccination practice and continues to recommend that eligible individuals who have not yet received a bivalent mRNA vaccine booster dose, should receive one.<sup>16</sup>
- While the effectiveness of COVID-19 vaccines wanes with time, protection against severe outcomes such as hospitalization and death is higher and better-maintained relative to protection against infection.<sup>10,11,19-23</sup> Another dose of vaccine provides additional protection after time has elapsed since the last dose; this has also been shown for bivalent booster doses.
  - Across jurisdictions, recent data have demonstrated the additional protection against hospitalization gained with a bivalent vaccine, including in periods of Omicron BA.4/BA.5 or BQ.1 dominance. In the United Kingdom, a BA.1-containing bivalent vaccine demonstrated added protection against hospitalization in those aged 50 years and older compared to those with two doses at least six months ago.<sup>20</sup> Similarly, additional protection against hospitalization was demonstrated for those receiving a BA.1 or BA.4/5-containing bivalent booster as a fourth dose relative to those who had received three doses only in a study in Nordic countries.<sup>24</sup> In the US, the vaccine effectiveness against hospitalization among those who received a BA.4/BA.5-containing bivalent booster was higher compared to those with past monovalent vaccination only.<sup>25,26</sup>
  - Early estimates of BA.4/BA.5-containing bivalent boosters against XBB/XBB.1.5 symptomatic infection (the variants predicted to be dominant in Ontario in the spring of 2023<sup>27</sup>) demonstrate added protection relative to those who had received monovalent vaccine doses only; these results were similar to those related to protection against BA.5 symptomatic infection.<sup>28</sup> The duration of this additional protection against XBB/XBB.1.5 is unclear, as is protection against XBB/XBB.1.5-related hospitalization.

## Implementation considerations related to additional doses

- The majority of the population in Ontario over the age of five years remain eligible for their fall booster dose. As of January 29, 2023, 21.1% of those over the age of five years have received a fall booster dose (i.e., received after September 1, 2022), with uptake increasing with age.<sup>29</sup> Only half (54.9%) of those over 80 years of age in Ontario have received a fall booster dose. Overall in Ontario, the vast majority of fall booster doses (94.4%) were a bivalent vaccine product.<sup>29</sup>
- Coverage within each age group declines with each additional booster dose.<sup>30,31</sup> Ongoing efforts are needed to improve coverage, as well as equitable uptake and access to COVID-19 immunization services, which should include consultation and partnerships with marginalized communities and groups in Ontario.
- In alignment with immunization technical advisory groups, including Canada's National Advisory Committee on Immunization, and in keeping with immunologic principles, a six-month interval between previous infection or last vaccine dose should be used to inform the timing of spring booster doses.<sup>6</sup> Extended intervals between doses of COVID-19 vaccines (or infection and vaccination) may result in an improved immune response relative to shorter intervals.<sup>6,32</sup> Further, a six-month interval will facilitate alignment with a spring 2023 program as the fall 2022 COVID-19 vaccine booster program began in Ontario in September, and may also assist in alignment with any potential fall booster program recommendations that may be made in the future.

## References

1. Ontario Agency for Health Protection and Promotion (Public Health Ontario), Ontario Immunization Advisory Committee. Considerations for the 2023 COVID-19 vaccine program in Ontario [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [cited 2023 Feb 27]. Available from: [https://www.publichealthontario.ca/-/media/Documents/nCoV/Vaccines/2023/02/oiac-considerations-2023-covid-19-vaccine-program-ontario.pdf?rev=a9acb37632a04d8880c74dc925fef690&sc\\_lang=en](https://www.publichealthontario.ca/-/media/Documents/nCoV/Vaccines/2023/02/oiac-considerations-2023-covid-19-vaccine-program-ontario.pdf?rev=a9acb37632a04d8880c74dc925fef690&sc_lang=en)
2. Public Health Agency of Canada. Statement from the Council of Chief Medical Officers of Health (CCMOH) on the next phase of the COVID-19 pandemic response [Internet]. Ottawa, ON: Government of Canada; 2022 [modified 2022 Feb 14; cited 2023 Feb 27]. Available from: <https://www.canada.ca/en/public-health/news/2022/02/statement-from-the-council-of-chief-medical-officers-of-health-ccmoh-on-the-next-phase-of-the-covid-19-pandemic-response.html>
3. Ontario. Ministry of Health. COVID-19 vaccine guidance [Internet]. Toronto, ON: King's Printer for Ontario; 2022 [cited 2023 Feb 27]. Available from: [https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19\\_vaccine\\_administration.pdf](https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19_vaccine_administration.pdf)
4. Ontario Newsroom; Ministry of Health. Ontario expanding fourth-dose eligibility [Internet]. News release. Toronto, ON: King's Printer for Ontario; 2022 Apr 6 [cited 2023 Feb 27]. Available from: <https://news.ontario.ca/en/release/1001961/ontario-expanding-fourth-dose-eligibility>
5. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Weekly epidemiologic summary: COVID-19 in Ontario – January 19 to February 4, 2023 [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [cited 2023 Feb 27]. Available from: [https://www.publichealthontario.ca/-/media/Documents/nCoV/Archives/Weekly-EPI/2023/02/weekly-epi-summary-covid-ontario-feb-10.pdf?rev=c62464f6c8c24d70bf94db3a36b0c007&sc\\_lang=en](https://www.publichealthontario.ca/-/media/Documents/nCoV/Archives/Weekly-EPI/2023/02/weekly-epi-summary-covid-ontario-feb-10.pdf?rev=c62464f6c8c24d70bf94db3a36b0c007&sc_lang=en)
6. Public Health Agency of Canada; National Advisory Committee on Immunization. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): guidance on COVID-19 vaccine booster doses: initial considerations for 2023 [Internet]. Ottawa, ON: Government of Canada; 2023 [cited 2023 Feb 27]. Available from: <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccine-booster-doses-initial-considerations-2023.pdf>
7. Vo AD, La J, Wu JT-Y, Strymish JM, Ronan M, Brophy M, et al. Factors associated with severe COVID-19 among vaccinated adults treated in US veterans affairs hospitals. JAMA Netw Open. 2022;5(10):e2240037. Available from: <https://doi.org/10.1001/jamanetworkopen.2022.40037>
8. Velásquez García HA, Adu PA, Harrigan S, Wilton J, Rasali D, Binka M, et al. Risk factors for COVID-19 hospitalization after COVID-19 vaccination: a population-based cohort study in Canada. Int J Infect Dis. 2023;127:116-23. Available from: <https://doi.org/10.1016/j.ijid.2022.12.001>

9. Centers for Disease Control and Prevention (CDC). Update on current epidemiology of the COVID-19 pandemic and SARS-CoV-2 variants [Internet]. Atlanta, GA: CDC; 2022 [cited 2023 Feb 27]. Available from: <https://www.fda.gov/media/164814/download>
10. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-COV-2 infection and hybrid immunity against the Omicron variant and severe disease: a systematic review and meta-regression. *Lancet Infect Dis*. 2023;S1473-3099(22):00801-5. Available from: [https://doi.org/10.1016/S1473-3099\(22\)00801-5](https://doi.org/10.1016/S1473-3099(22)00801-5)
11. Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Fafard J, et al. Prior infection-and/or vaccine-induced protection against Omicron Ba.1, Ba.2 and BA.4/BA.5-related hospitalisations in older adults: a test-negative case-control study in Quebec, Canada [Internet]. medRxiv 22283740 [Preprint]. 2022 Dec 27 [cited 2023 Feb 27]. Available from: <https://doi.org/10.1101/2022.12.21.22283740>
12. COVID-19 Immunity Task Force. Seroprevalence in Canada [Internet]. Montreal, QC: McGill University; 2022 [cited 2023 Feb 27]. Available from: <https://www.covid19immunitytaskforce.ca/seroprevalence-in-canada/>
13. Ontario Newsroom; Ministry of Health. Ontarians aged 18+ eligible for bivalent COVID-19 booster dose [Internet]. News release. Toronto, ON: King's Printer for Ontario; 2022 Sep 12 [cited 2023 Feb 27]. Available from: <https://news.ontario.ca/en/release/1002277/ontarians-aged-18-eligible-for-bivalent-covid-19-booster-dose>
14. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Risk assessment for Omicron sub-lineage XBB\* (including XBB.1 and XBB.1.5) (as of January 25, 2023). 1<sup>st</sup> revision [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [cited 2023 Feb 27]. Available from: <https://www.publichealthontario.ca/-/media/Documents/nCoV/voc/2023/02/risk-assessment-omicron-sub-lineage-xbb1-xbb15-feb-02.pdf>
15. Food and Drug Administration (FDA). FDA announces Evusheld is not currently authorized for emergency use in the U.S. [Internet]. Silver Spring, MD: FDA; 2023 [updated 2023 Jan 26; cited 2023 Feb 27]. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us>
16. Centers for Disease Control and Prevention (CDC). CDC & FDA identify preliminary COVID-19 vaccine safety signal for persons aged 65 years and older [Internet]. Atlanta, GA: CDC; 2023 [updated 2023 Jan 13; cited 2023 Feb 27]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/bivalent-boosters.html>
17. Centers for Disease Control and Prevention (CDC). COVID-19 mRNA bivalent booster vaccine safety [Internet]. Atlanta, GA: CDC; 2023 [cited 2023 Feb 27]. Available from: <https://www.fda.gov/media/164811/download>
18. Public Health Agency of Canada. Reported side effects following COVID-19 vaccination in Canada [Internet]. Ottawa, ON: Government of Canada; 2023 [modified 2023 Feb 17; cited 2023 Mar 13]. Available from: <https://health-infobase.canada.ca/covid-19/vaccine-safety/>

19. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Confirmed cases of COVID-19 following vaccination in Ontario: December 14, 2020 to January 29, 2023 [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [cited 2023 Feb 27]. Available from: [https://www.publichealthontario.ca/-/media/Documents/nCoV/epi/covid-19-epi-confirmed-cases-post-vaccination.pdf?rev=23928237837946ca8b3145087cbdadc6&sc\\_lang=en](https://www.publichealthontario.ca/-/media/Documents/nCoV/epi/covid-19-epi-confirmed-cases-post-vaccination.pdf?rev=23928237837946ca8b3145087cbdadc6&sc_lang=en)
20. UK Health Security Agency. COVID-19 vaccine surveillance report: week 2 [Internet]. London, UK: Crown Copyright; 2023 [cited 2023 Feb 27]. Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1134075/Vaccine-surveillance-report-week-2-2023.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1134075/Vaccine-surveillance-report-week-2-2023.pdf)
21. Grewal R, Nguyen L, Buchan SA, Wilson SE, Nasreen S, Austin PC, et al. Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes [Internet]. medRxiv 22281766 [Preprint]. 2022 Nov 1 [cited 2023 Feb 27]. Available from: <https://doi.org/10.1101/2022.10.31.22281766>
22. Grewal R, Nguyen L, Buchan SA, Wilson SE, Costa AP, Kwong JC. Effectiveness and duration of protection of a fourth dose of coronavirus disease 2019 messenger RNA vaccine among long-term care residents in Ontario, Canada. *J Infect Dis*. 2022 Dec 3 [Epub ahead of print]. Available from: <https://doi.org/10.1093/infdis/jiac468>
23. Link-Gelles R, Levy ME, Natarajan K, Reese SE, Naleway AL, Grannis SJ, et al. Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods [Internet]. medRxiv 22280459 [Preprint]. 2022 Oct 5 [cited 2023 Feb 27]. Available from: <https://doi.org/10.1101/2022.10.04.22280459>
24. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries [Internet]. medRxiv 23284764 [Preprint]. 2023 Jan 19 [cited 2023 Feb 27]. Available from: <https://doi.org/10.1101/2023.01.19.23284764>
25. Surie D, DeCuir J, Zhu Y, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated hospitalization among immunocompetent adults aged ≥65 years — IVY Network, 18 states, September 8–November 30, 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71:1625-30. Available from: <http://dx.doi.org/10.15585/mmwr.mm715152e2>
26. Tenforde MW, Weber ZA, Natarajan K, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults — VISION Network, nine states, September–November 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71:1616-24. Available from: <http://dx.doi.org/10.15585/mmwr.mm715152e1>
27. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Epidemiologic summary: SARS-CoV-2 whole genome sequencing in Ontario, February 3, 2023 [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [cited 2023 Feb 27]. Available from: [https://www.publichealthontario.ca/-/media/Documents/nCoV/Archives/Genome/2023/02/SARS-CoV-2-genomic-surveillance-report-2023-02-07.pdf?rev=de6225afae6c4190b0543d84e4971843&sc\\_lang=en](https://www.publichealthontario.ca/-/media/Documents/nCoV/Archives/Genome/2023/02/SARS-CoV-2-genomic-surveillance-report-2023-02-07.pdf?rev=de6225afae6c4190b0543d84e4971843&sc_lang=en)

28. Link-Gelles R, Ciesla AA, Roper LE, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5– and XBB/XBB.1.5–related sublineages among immunocompetent adults — increasing community access to testing program, United States, December 2022–January 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72:119-24. Available from: <http://dx.doi.org/10.15585/mmwr.mm7205e1>
29. Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVaxON [dataset]. Toronto, ON: King’s Printer for Ontario; 2023 [extracted 2023 Jan 30].
30. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Ontario COVID-19 data tool [Internet]. Toronto, ON: King’s Printer for Ontario; 2023 [cited 2023 Feb 27]. Available from: <https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/COVID-19-Data-Surveillance/COVID-19-Data-Tool?tab=vaccine>
31. Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 vaccine uptake in Ontario: December 14, 2020 to January 29, 2023 [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [updated 2023 Feb 27; cited 2023 Feb 27]. Available from: [https://www.publichealthontario.ca/-/media/Documents/nCoV/epi/covid-19-vaccine-uptake-ontario-epi-summary.pdf?rev=f0b8e786c2f146a9837137a461cbdfb6&sc\\_lang=en](https://www.publichealthontario.ca/-/media/Documents/nCoV/epi/covid-19-vaccine-uptake-ontario-epi-summary.pdf?rev=f0b8e786c2f146a9837137a461cbdfb6&sc_lang=en)
32. Bates TA, Leier HC, McBride SK, Schoen D, Lyski ZL, Xthona Lee DD, et al. An extended interval between vaccination and infection enhances hybrid immunity against SARS-COV-2 variants. *JCI Insight.* 2023:e165265. Available from: <https://doi.org/10.1172/jci.insight.165265>

## About the Ontario Immunization Advisory Committee

The OIAC is a multidisciplinary scientific advisory body that provides evidence-based advice to Public Health Ontario (PHO) on vaccines and immunization matters including vaccine program implementation in Ontario, priority populations and clinical guidance. The focus of the OIAC's work is on publicly-funded vaccines and immunization programs in Ontario, including COVID-19 and those under consideration for new programming. For more information about the OIAC and its members contact [secretariat@oahpp.ca](mailto:secretariat@oahpp.ca)

## Acknowledgements

This statement was prepared by the OIAC Secretariat, on behalf of the OIAC. OIAC acknowledges the contribution of PHO staff within Health Protection, Communications Services, and Library Services.

## OIAC Members

Dr. Jessica Hopkins, co-chair  
Chief Health Protection and  
Emergency Preparedness Officer  
Public Health Ontario

Dr. Jeffrey Pernica, co-chair  
Head, Division of Infectious Disease  
Department of Pediatrics  
McMaster University

Dr. Juthaporn Cowan  
Associate Scientist  
The Ottawa Hospital Research Institute

Dr. Vinita Dubey  
Associate Medical Officer of Health  
Toronto Public Health

Dr. Julie Emili  
Associate Medical Officer of Health  
Region of Waterloo

Susie Jin  
Pharmacist

Dr. Allison McGeer  
Professor, Laboratory Medicine and  
Pathobiology  
University of Toronto  
Dalla Lana School of Public Health

Dr. Justin Presseau  
Scientist  
The Ottawa Hospital Research Institute

Dr. Maurianne Reade  
Family Physician; Associate Professor  
Northern Ontario School of Medicine

Richard San Cartier  
Clinical Team Lead  
N'Mninoeyaa Aboriginal Health Access  
Centre

Fairleigh Seaton  
Director, Infectious Disease Prevention  
and Environmental Health  
Kingston, Frontenac and Lennox &  
Addington Public Health

## OIAC Ex-Officio Members

Tara Harris  
Manager  
Immunization and Emergency Preparedness  
Public Health Ontario

Robert Lerch  
Director (Acting)  
Health Protection and Surveillance Policy  
and Programs Branch  
Ministry of Health

Dr. Fareen Karachiwalla  
Associate Chief Medical Officer of  
Health (Acting)  
Office of Chief Medical Officer of Health,  
Public Health  
Ministry of Health

Dr. Sarah Wilson  
Public Health Physician  
Public Health Ontario

## Citation

Ontario Agency for Health Protection and Promotion (Public Health Ontario), Ontario Immunization Advisory Committee. Recommendations: high-risk spring 2023 COVID-19 vaccine booster dose program in Ontario. Toronto, ON: King's Printer for Ontario; 2023.

## Disclaimer

This document was prepared by the Ontario Immunization Advisory Committee (OIAC) for Public Health Ontario. The OIAC provides evidence-based advice to Public Health Ontario on vaccines and immunization matters. OIAC work is guided by the evidence available at the time this document was prepared. The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use. This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes may be made to this document without prior and expressed written permission from PHO. Questions about the information in this document can be sent to [secretariat@oahpp.ca](mailto:secretariat@oahpp.ca).

## Public Health Ontario

Public Health Ontario is an agency of the Government of Ontario dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit [publichealthontario.ca](http://publichealthontario.ca)

©King's Printer for Ontario, 2023

